Physician profile
Subbarao Choudry
NPI 1255506366
$6,318.82
in general payments reported to CMS, 2019-2025
37 companies · $916 in 2025
The $916 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $335 · 2021: $1,311 · 2022: $2,036 · 2023: $904 · 2024: $503 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,932.02 | 2020-2025 | Lux-Dx Insertable Cardiac Monitor, Farapulse, Accolade Sr |
| Janssen Pharmaceuticals, INC | $610.28 | 2019-2023 | Xarelto |
| Biotronik INC. | $597.43 | 2021-2022 | |
| Biosense Webster, INC. | $518.88 | 2021-2025 | Carto 3 |
| Medtronic, INC. | $482.34 | 2021-2025 | Linq II, Affera Mapping System |
| Abbott Laboratories | $398.76 | 2019-2025 | Cardiomems, Aveir |
| Pfizer INC. | $287.46 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $227.48 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $225.85 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $188.38 | 2019-2023 | Farxiga |
| Medicomp INC | $122.42 | 2022-2025 | Telepatch Cardiac Monitor |
| Arbor Pharmaceuticals, INC. | $98.53 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $53.25 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.64 | 2023 | Eliquis |
| Exact Sciences Corporation | $51.02 | 2023-2025 | Cologuard Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $45.31 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $41.00 | 2024 | Arcalyst |
| Lundbeck LLC | $35.10 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $24.73 | 2023 | Inpefa |
| Shire North American Group INC | $22.25 | 2019 | |
| Electromed, INC. | $22.06 | 2019 | |
| Glaxosmithkline, LLC. | $21.96 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.09 | 2025 | Edarbi |
| Daiichi Sankyo INC. | $20.59 | 2024 | Injectafer |
| Amarin Pharma, INC. | $20.20 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $20.03 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.24 | 2022 | |
| Astellas Pharma US INC | $18.85 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.21 | 2022 | |
| Akcea Therapeutics, INC. | $17.99 | 2019 | |
| Lilly USA, LLC | $17.72 | 2023 | Mounjaro |
| Ultragenyx Pharmaceutical INC. | $15.81 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.47 | 2021 | |
| Therapeuticsmd, INC. | $15.42 | 2021 | |
| Janssen Biotech, INC. | $15.17 | 2021 | |
| Novo Nordisk INC | $13.81 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subbarao Choudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.